Works by ROSENTHAL, NORM

Results: 16

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

Published in:

Annals of the New York Academy of Sciences, 2015, v. 1358, n. 1, p. 28, doi. 10.1111/nyas.12852

By:

Rosenthal, Norm;
Meininger, Gary;
Ways, Kirk;
Polidori, David;
Desai, Mehul;
Qiu, Rong;
Alba, Maria;
Vercruysse, Frank;
Balis, Dainius;
Shaw, Wayne;
Edwards, Robert;
Bull, Scott;
Di Prospero, Nicholas;
Sha, Sue;
Rothenberg, Paul;
Canovatchel, William;
Demarest, Keith

Publication type:

Article

Sodium‐glucose co‐transporter‐2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta‐analysis.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 252, doi. 10.1111/dom.14197

By:

Li, Chao;
Zhou, Zien;
Neuen, Brendon L.;
Yu, Jie;
Huang, Yuli;
Young, Tamara;
Li, Jingwei;
Li, Lin;
Perkovic, Vlado;
Jardine, Meg J.;
Keay, Lisa;
Markoulli, Maria;
Rosenthal, Norm;
Capuano, George;
Yavin, Yshai;
Neal, Bruce;
Arnott, Clare

Publication type:

Article

Comment on "Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D)"

Published in:

2019

By:

Ryan, Patrick B.;
Rosenthal, Norm

Publication type:

Letter to the Editor

Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: A retrospective cohort study.

Published in:

Diabetes, Obesity & Metabolism, 2018, v. 20, n. 3, p. 582, doi. 10.1111/dom.13115

By:

Yuan, Zhong;
Defalco, Frank J.;
Ryan, Patrick B.;
Schuemie, Martijn J.;
Stang, Paul E.;
Berlin, Jesse A.;
Desai, Mehul;
Rosenthal, Norm

Publication type:

Article

Comment on: Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: A network and cumulative meta-analysis of randomized controlled trials.

Published in:

Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1823, doi. 10.1111/dom.13035

By:

Canovatchel, William;
Davidson, Jennifer;
Rosenthal, Norm

Publication type:

Article

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.

Published in:

Diabetes, Obesity & Metabolism, 2017, v. 19, n. 7, p. 926, doi. 10.1111/dom.12924

By:

Neal, Bruce;
Perkovic, Vlado;
Mahaffey, Kenneth W.;
Fulcher, Greg;
Erondu, Ngozi;
Desai, Mehul;
Shaw, Wayne;
Law, Gordon;
Walton, Marc K.;
Rosenthal, Norm;
de Zeeuw, Dick;
Matthews, David R.

Publication type:

Article

Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.

Published in:

Diabetes, Obesity & Metabolism, 2017, v. 19, n. 6, p. 897, doi. 10.1111/dom.12876

By:

Desai, Mehul;
Yavin, Yshai;
Balis, Dainius;
Sun, Don;
Xie, John;
Canovatchel, William;
Rosenthal, Norm

Publication type:

Article

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.

Published in:

2016

By:

Bilezikian, John P;
Watts, Nelson B;
Usiskin, Keith;
Polidori, David;
Fung, Albert;
Sullivan, Daniel;
Rosenthal, Norm

Publication type:

journal article

185-OR: Longitudinal Changes in KidneyIntelX and Association with Progressive Decline in Kidney Function in the CANVAS Trial.

Published in:

Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-185-OR

By:

LAM, DAVID W.;
NADKARNI, GIRISH N.;
NEAL, BRUCE;
MAHAFFEY, KENNETH W.;
ROSENTHAL, NORM;
HANSEN, MICHAEL K.;
HEERSPINK, HIDDO L.;
COCA, STEVEN

Publication type:

Article

139-LB: The Redox Balance Predicts Both Cardiovascular (CV) and Renal Outcomes in CANVAS.

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-139-LB

By:

FERRANNINI, ELE;
BALDI, SIMONA;
SCOZZARO, TIZIANA;
TESFAYE, FISSEHA;
SHAW, WAYNE;
ROSENTHAL, NORM;
MAHAFFEY, KENNETH W.;
NEAL, BRUCE;
PERKOVIC, VLADO;
HANSEN, MICHAEL K.

Publication type:

Article

27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease.

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-27-OR

By:

LI, JINGWEI;
JARDINE, MEG J.;
NEAL, BRUCE;
HEERSPINK, HIDDO L.;
CANNON, CHRISTOPHER;
AGARWAL, RAJIV;
BAKRIS, GEORGE;
CHARYTAN, DAVID M.;
ZEEUW, DICK DE;
EDWARDS, ROBERT;
GREENE, TOM;
LEVIN, ADEERA;
POLLOCK, CAROL A.;
ROSENTHAL, NORM;
WHEELER, DAVID C.;
ZHANG, HONG;
ZINMAN, BERNARD;
PERKOVIC, VLADO;
MAHAFFEY, KENNETH W.;
ARNOTT, CLARE

Publication type:

Article

26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE.

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-26-OR

By:

OSHIMA, MEGUMI;
JARDINE, MEG J.;
AGARWAL, RAJIV;
BAKRIS, GEORGE;
CANNON, CHRISTOPHER;
CHARYTAN, DAVID M.;
ZEEUW, DICK DE;
EDWARDS, ROBERT;
GREENE, TOM;
LEVIN, ADEERA;
MAHAFFEY, KENNETH W.;
NEAL, BRUCE;
POLLOCK, CAROL A.;
ROSENTHAL, NORM;
WHEELER, DAVID C.;
ZHANG, HONG;
ZINMAN, BERNARD;
PERKOVIC, VLADO;
HEERSPINK, HIDDO L.

Publication type:

Article

1123-P: Stress Cardiac Biomarkers and Adverse Cardiac Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS).

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1123-P

By:

SATTAR, NAVEED;
XU, JIALIN;
BUTLER, JAVED;
MAHAFFEY, KENNETH W.;
SHAW, WAYNE;
ROSENTHAL, NORM;
GUTSTEIN, DAVID E.;
HANSEN, MICHAEL K.;
JANUZZI JR., JAMES

Publication type:

Article

1120-P: Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial.

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1120-P

By:

LI, JINGWEI;
SEN, TAHA;
NEAL, BRUCE;
NEUEN, BRENDON L.;
PERKOVIC, VLADO;
ZEEUW, DICK DE;
MAHAFFEY, KENNETH W.;
YAVIN, YSHAI;
ROSENTHAL, NORM;
HANSEN, MICHAEL K.;
HEERSPINK, HIDDO L.

Publication type:

Article

1098-P: Biomarkers of Tubular Injury and Effects of Canagliflozin in the CANVAS Trial.

Published in:

Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1098-P

By:

SEN, TAHA;
LI, JINGWEI;
NEAL, BRUCE;
NEUEN, BRENDON L.;
JARDINE, MEG J.;
IX, JOACHIM;
SHLIPAK, MICHAEL G.;
PERKOVIC, VLADO;
YAVIN, YSHAI;
ROSENTHAL, NORM;
HANSEN, MICHAEL K.;
HEERSPINK, HIDDO L.

Publication type:

Article

1546-P: Acute Pancreatitis (AP) with Canagliflozin (CANA) vs. Other Antihyperglycemic Agents (AHAs): An Observational Study.

Published in:

Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1546-P

By:

YUAN, ZHONG;
DEFALCO, FRANK;
WANG, LU;
HESTER, LAURA L.;
SWERDEL, JOEL N.;
FREEDMAN, AMY;
RYAN, PATRICK;
SCHUEMIE, MARTIJN;
QIU, ROSE;
YEE, JACQUELINE;
MEININGER, GARY;
BERLIN, JESSE A.;
ROSENTHAL, NORM

Publication type:

Article